View Filing Data

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	May 12, 2020
Cover [Abstract]
Entity Registrant Name	STRATA Skin Sciences, Inc.
Entity Central Index Key	0001051514
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		33,714,362
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Address, State or Province	PA

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 8,150	$ 8,129
Restricted cash	7,481	7,500
Accounts receivable, net of allowance for doubtful accounts of $186 and $184, respectively	3,208	4,386
Inventories	3,471	3,027
Prepaid expenses and other current assets	487	513
Total current assets	22,797	23,555
Property and equipment, net	5,379	5,369
Operating lease right-of-use assets, net	1,235	1,314
Intangible assets, net	7,503	7,955
Goodwill	8,803	8,803
Other assets	330	347
Total assets	46,047	47,343
Current liabilities:
Note payable	7,275	7,275
Accounts payable	2,102	1,880
Other accrued liabilities	5,150	5,134
Current portion of operating lease liabilities	343	313
Deferred revenues	1,934	2,832
Total current liabilities	16,804	17,434
Long-term liabilities:
Deferred tax liability	88	0
Long-term operating lease liabilities, net	988	1,078
Other liabilities	119	178
Total liabilities	17,999	18,690
Commitments and contingencies (see Note 15)
Stockholders' equity:
Common Stock, $.001 par value, 150,000,000 shares authorized; 33,714,362 and 32,932,273 shares issued and outstanding at March 31, 2020 and, December 31, 2019, respectively	34	33
Additional paid-in capital	243,610	243,180
Accumulated deficit	(215,596)	(214,561)
Total stockholders' equity	28,048	28,653
Total liabilities and stockholders' equity	46,047	47,343
Series C Convertible Preferred Stock [Member]
Stockholders' equity:
Series C Convertible Preferred Stock, $.10 par value, 10,000,000 shares authorized; - and 2,103 shares issued and outstanding at March 31, 2020 and, December 31, 2019, respectively	$ 0	$ 1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Allowance for doubtful accounts	$ 186	$ 184
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock shares issued on exercise of options (in shares)	33,714,362	32,932,273
Common stock, shares outstanding (in shares)	33,714,362	32,932,273
Series C Convertible Preferred Stock [Member]
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	2,103
Preferred stock, shares outstanding (in shares)	0	2,103

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Revenues, net	$ 6,730	$ 7,483
Cost of revenues	2,331	2,874
Gross profit	4,399	4,609
Operating expenses:
Engineering and product development	292	304
Selling and marketing	2,953	3,066
General and administrative	2,102	2,480
Total operating expenses	5,347	5,850
Loss from operations	(948)	(1,241)
Other income (expense), net:
Interest income (expense), net	1	(135)
Other (expense) income, net	1	(135)
Loss before income taxes	(947)	(1,376)
Income tax (expense) benefit	(88)	43
Net loss	(1,035)	(1,333)
Loss attributable to common shares	(1,018)	(1,216)
Loss attributable to Preferred Series C shares	$ (17)	$ (117)
Loss per common share:
Basic (in dollars per share)	$ (0.03)	$ (0.04)
Diluted (in dollars per share)	$ (0.03)	$ (0.04)
Shares used in computing loss per common share:
Basic (in shares)	33,164,321	30,703,501
Diluted (in shares)	33,164,321	30,703,501
Loss per Preferred Series C share - basic and diluted (in dollars per share)	$ (11.42)	$ (14.72)
Shares used in computing loss per basic and diluted Preferred Series C Shares (in shares)	1,480	7,944

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Convertible Preferred Stock - Series C [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Beginning balance at Dec. 31, 2018	$ 1	$ 30	$ 241,988	$ (210,771)	$ 31,248
Beginning balance (in shares) at Dec. 31, 2018	9,968	29,943,086
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 0	$ 0	323	0	323
Conversion of convertible preferred stock into common stock	$ 0	$ 1	(1)	0	0
Conversion of convertible preferred stock into common stock (in shares)	(3,090)	1,148,698
Exercise of stock options	$ 0	$ 0	0	0	0
Exercise of stock options (in shares)	0	28,824
Net loss	$ 0	$ 0	0	(1,333)	(1,333)
Ending balance at Mar. 31, 2019	$ 1	$ 31	242,310	(212,104)	30,238
Ending balance (in shares) at Mar. 31, 2019	6,878	31,120,608
Beginning balance at Dec. 31, 2019	$ 1	$ 33	243,180	(214,561)	28,653
Beginning balance (in shares) at Dec. 31, 2019	2,103	32,932,273
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 0	$ 0	430	0	430
Conversion of convertible preferred stock into common stock	$ (1)	$ 1	0	0	0
Conversion of convertible preferred stock into common stock (in shares)	(2,103)	782,089
Net loss	$ 0	$ 0	0	(1,035)	(1,035)
Ending balance at Mar. 31, 2020	$ 0	$ 34	$ 243,610	$ (215,596)	$ 28,048
Ending balance (in shares) at Mar. 31, 2020	0	33,714,362

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash Flows From Operating Activities:
Net loss	$ (1,035)	$ (1,333)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	1,038	1,204
Amortization of right-of-use assets	79	93
Provision for doubtful accounts	2	(7)
Loss on disposal of property and equipment and lasers placed in service	0	22
Stock-based compensation	430	323
Deferred taxes	88	(42)
Amortization of debt discount	0	7
Amortization of deferred financing costs	0	27
Changes in operating assets and liabilities:
Accounts receivable	1,176	(175)
Inventories	(444)	(327)
Prepaid expenses and other assets	43	142
Accounts payable	222	281
Other accrued liabilities	16	224
Other liabilities	(59)	9
Operating lease liabilities	(60)	(76)
Deferred revenues	(898)	(36)
Net cash provided by operating activities	598	336
Cash Flows From Investing Activities:
Lasers placed-in-service	(596)	(434)
Net cash used in investing activities	(596)	(434)
Net increase (decrease) in cash and cash equivalents and restricted cash	2	(98)
Cash, cash equivalents and restricted cash, beginning of period	15,629	16,487
Cash, cash equivalents and restricted cash, end of period	15,631	16,389
Cash and cash equivalents	8,150	16,389
Restricted cash	7,481	0
Supplemental information of cash and non-cash transactions:
Cash paid for interest	52	201
Lease liabilities arising from obtaining right-of-use assets	$ 0	$ 848

The Company

3 Months Ended

Mar. 31, 2020

The Company [Abstract]

The Company

Note 1

The Company:

Background

STRATA Skin Sciences (the “Company”) is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.

The XTRAC is an ultraviolet light excimer laser system utilized to treat psoriasis, vitiligo and other skin diseases. The XTRAC excimer laser system received clearance from the United States Food and Drug Administration (the “FDA”) in 2000. As of March 31, 2020, there were 822 XTRAC systems placed in dermatologists' offices in the United States under the Company's recurring revenue business model. The XTRAC systems deployed under the recurring revenue model generate revenue on a per procedure basis or include a fixed payment over an agreed upon period with a capped number of treatments, which if exceeded would incur additional fees. The per-procedure charge is inclusive of the use of the system and the services provided by the Company to the customer which includes system maintenance, and other services. The VTRAC Excimer Lamp system, offered in addition to the XTRAC system internationally, provides targeted therapeutic efficacy demonstrated by excimer technology with a lamp system.

In July 2019, the Company signed a direct distribution agreement with its Korean distributor for a combination of direct capital sales and recurring revenues for the country of South Korea. The term is for twelve months with up to four additional twelve-month terms subject to certain conditions.

In late 2019, there was an outbreak of a new strain of coronavirus (“COVID-19”) which appears to have originated from Wuhan, China. COVID-19 has since spread to over 100 countries, including every state in the United States. On March 11, 2020, the World Health Organization declared the COVID-19 outbreak a global pandemic and on March 13, 2020 the United States declared a national emergency with respect to COVID-19. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains, constrained work force participation and created significant volatility and disruption of financial markets. In addition, the pandemic lead to the suspension of elective procedures in the U.S. and to the temporary closure of many physician practices. The extent of the impact of the COVID-19 pandemic on the Company’s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frames, will depend on future developments, including the duration and spread of the COVID-19 outbreak, continued restrictions on travel and transport and the continued impact on worldwide economic and geopolitical conditions, all of which are uncertain and cannot be predicted.

Domestically, as the procedures in which the Company’s devices are used are elective in nature; and as social distancing, travel restrictions, quarantines and other restrictions have become prevalent in the United States, this has had a negative impact on the Company’s recurring revenue model and its financial position and cash flow. The virus has disrupted the supply chain from China and other countries and the Company depends upon its supply chain to provide a steady source of components to manufacture and repair our devices.

To mitigate the impact of COVID-19 the Company has taken a variety of measures to ensure the availability and functioning of its critical infrastructure by implementing business continuity plans, and to promote the safety and security of its employees while complying with various government mandates, including work-from-home arrangements and social-distancing initiatives to reduce the transmission of COVID-19, such as providing face masks for employees at facilities significantly impacted and requiring on-site body temperature monitoring before entering certain facilities. In addition, the Company has created programs utilizing its direct to consumer advertising and call center to contact patients and partner clinics to restart the Company’s partners’ businesses. In order to conserve its cash during this time period, the Company has furloughed employees, reduced all discretionary spending and reduced all inventory purchases and delayed payments to vendors. Delayed payments to vendors were approximately $400 as of March 31, 2020. See Note 2 Liquidity for discussion on Company liquidity.

In the event our own employees are impacted through direct or ancillary contact with a person who has the virus, we may need to devise other methods of transacting business in our offices by working from home and or potentially ceasing operations for a period of time.

Basis of Presentation:

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned, inactive subsidiary in India. All significant intercompany balances and transactions have been eliminated in consolidation.

Unaudited Interim Condensed Consolidated Financial Statements

The accompanying unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC") for interim financial reporting. These condensed consolidated statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to fairly present the results of the interim periods. The condensed consolidated balance sheet at December 31, 2019, has been derived from the audited consolidated financial statements at that date. Operating results and cash flows for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2020 or any other future period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been omitted in accordance with the rules and regulations for interim reporting of the SEC. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019 (the “2019 Form 10-K”), and other forms filed with the SEC from time to time. Dollar amounts included herein are in thousands, except per share data.

Reclassifications

Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have a material impact on the Company’s equity, results of operations, or cash flows.

Significant Accounting Policies

The significant accounting policies used in preparation of these condensed consolidated financial statements are disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019, and there have been no changes to the Company’s significant accounting policies during the three months ended March 31, 2020.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of March 31, 2020, the more significant estimates include (1) revenue recognition, in regards to deferred revenues and the contract term and valuation allowances of accounts receivable, (2) the inputs used in the impairment analyses of goodwill, (3) the estimated useful lives of intangible assets and property and equipment, (4) the inputs used in determining the fair value of equity-based awards, (5) the valuation allowance related to deferred tax assets, (6) the inventory reserves, (7) state sales and use tax accruals and (8) warranty claims.

Additionally, the full impact of the COVID-19 outbreak is unknown and cannot be reasonably estimated. However, management has made appropriate accounting estimates on certain accounting matters, which include the allowance for doubtful accounts, inventory valuation, carrying value of the goodwill and other long-lived assets, based on the facts and circumstances available as of the reporting date. The Company’s future assessment of the magnitude and duration of the COVID-19 outbreak, as well as other factors, could result in material impacts to the Company’s financial statements in future reporting periods.

Fair Value Measurements

The Company measures and discloses fair value in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 820, Fair Value Measurements and Disclosures (“ASC Topic 820”). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:

	•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
	•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
	•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors.

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

The fair value of cash and cash equivalents and restricted cash are based on their respective demand value, which are equal to the carrying value. The carrying value of all short-term monetary assets and liabilities is estimated to be approximate to their fair value due to the short-term nature of these instruments. As of March 31, 2020 and December 31, 2019, the carrying value of the note payable is estimated to approximate its fair value due to its short-term nature.

Earnings Per Share

The Company calculates loss per common share and Preferred Series C share in accordance with ASC 260, Earnings per Share. Under ASC 260, basic loss per common share and Preferred Series C share is calculated by dividing loss attributable to common shares and Preferred Series C shares by the weighted-average number of common shares and Preferred Series C shares outstanding during the reporting period and excludes dilution for potentially dilutive securities. Diluted loss per common share and Preferred Series C share gives effect to dilutive options, warrants and other potential common shares outstanding during the period.

The Company's Series C Convertible Preferred Stock are subordinate to all other securities at the same subordination level as common stock and they participate in all dividends and distributions declared or paid with respect to common stock of the Company, on an as-converted basis. Therefore, the Series C Convertible Preferred Shares meet the definition of common stock under ASC 260. Earnings per share is presented for each class of security meeting the definition of common stock. The loss is allocated to each class of security meeting the definition of common stock based on their contractual terms.

The following table presents the calculation of basic and diluted loss per share by each class of security for the three months ended March 31, 2020 and, 2019:

	Three Months Ended March 31, 2020						Three Months Ended March 31, 2019
	Common Stock			Series C Convertible Preferred Stock			Common Stock			Series C Convertible Preferred Stock

Loss attributable to each class	$	(1,018	)	$	(17	)	$	(1,216	)	$	(117	)

Weighted average number of shares outstanding during the period		33,164,321			1,480			30,703,501			7,944

Basic and Diluted loss per share	$	(0.03	)	$	(11.42	)	$	(0.04	)	$	(14.72	)

The Company considers its Series C Convertible Preferred Stock to be participating securities in the presentation of earnings per share. For the three months ended March 31, 2020 and 2019, diluted loss per common share and Series C Convertible Preferred Stock share is equal to the basic loss per common share and Series C Convertible Preferred Stock share, respectively, since all potentially dilutive securities are anti-dilutive.

The following table sets forth the weighted average of potential common stock equivalents outstanding during the three months ended March 31, 2020 and, 2019 that have been excluded from the loss per share calculation as their inclusion would have been anti-dilutive:

	Three Months Ended March 31,
	2020		2019
Common stock purchase warrants		749,901		2,233,192
Restricted stock units		169,023		129,576
Common stock options		4,908,038		4,321,932
Total		5,826,962		6,684,700

Accounting Pronouncements Recently Adopted

In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance eliminated Step 2 from the goodwill impairment test which was required in computing the implied fair value of goodwill. Instead, under the new amendments, an entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. If applicable, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss. The amendments in this guidance are effective for public business entities for annual and interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019 with early adoption permitted after January 1, 2017. The adoption of ASU No. 2017-04 on January 1, 2020 did not have an impact on the Company’s condensed consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The adoption of ASU No. 2018-13 on January 1, 2020 did not have a material effect on the Company’s condensed consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company condensed financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.

Liquidity	3 Months Ended
Liquidity	Mar. 31, 2020
Liquidity [Abstract]
Liquidity	Note 2 Liquidity The Company has been negatively impacted by the COVID-19 pandemic, has historically experienced recurring losses and has been dependent on raising capital from the sale of securities in order to continue to operate and meet the Company’s obligations in the ordinary course of business. Since the equity financing in May 2018 and the change in management, the Company has improved revenues, gross profit, generated positive cash flow from operations, refinanced its debt at a lower interest rate and received cash proceeds from the PPP loan (defined in Note 16 below). Management believes that the Company’s cash and cash equivalents, combined with the anticipated revenues from the sale or use of the Company’s products and the proceeds from the PPP loan, will be sufficient to satisfy our working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with our existing operations through the next 12 months following the date of the issuance of these unaudited condensed consolidated financial statements. However, the negative impact of the COVID-19 outbreak on the financial markets could interfere with our ability to access financing and on favorable terms.

Revenue Recognition

3 Months Ended

Mar. 31, 2020

Revenue Recognition [Abstract]

Revenue Recognition

Note 3

Revenue Recognition

In the Dermatology Recurring Procedures Segment the Company has two types of arrangements for its phototherapy treatment equipment as follows: (i) the Company places its lasers in a physician’s office at no charge to the physician, and generally charges the physician a fee for an agreed upon number of treatments; or (ii) the Company places its lasers in a physician’s office and charges the physician a fixed fee for a specified period of time not to exceed an agreed upon number of treatments; if that number is exceeded additional fees will have to be paid.

For the purposes of U.S. GAAP only, these two types of arrangements are treated under the guidance of ASC 842, Leases. While these arrangements are not contractually operating leases, since the Company sells the physician access codes in order to operate the treatment equipment, these arrangements are similar to operating leases for accounting purposes since the Company provides the customers limited rights to use the treatment equipment and the treatment equipment resides in the physician’s office and the Company may exercise the right to remove the equipment upon notice, under certain circumstances, while the physician controls the utility and output of such equipment during the term of the arrangement as it pertains to the use of access codes to treat the patients. The terms of the domestic arrangements are generally 36 months with automatic one-year renewals and include a termination clause that can be affected at any time by either party with 30 to 60-day notice. Amounts paid are generally non-refundable. For the first type of arrangement, sales of access codes are considered variable treatment code payments and are recognized as revenue over the estimated usage period of the agreed upon number of treatments. For the second type of arrangement, customers purchase access codes and revenue is recognized ratably on a straight-line basis as the lasers are being used over the term period specified in the agreement. Variable treatment code payments that will be paid only if the customer exceeds the agreed upon number of treatments are recognized only when such treatments are being exceeded and used. Internationally, through its Korean distributor, the Company sells access codes for a fixed amount on a monthly basis to end user customers and the terms are generally 48 months, with termination in the event of the customers’ failure to remit payments timely, and include a potential buy-out at the end of the term of the contract. Currently, this is the only foreign recurring revenue. Pre-paid amounts are recorded in deferred revenue and recognized as revenue over the lease term in the patterns described above. Under both methods, pricing is fixed with the customer. With respect to lease and non-lease components, the Company adopted the practical expedient to account for the arrangement as a single lease component.

In the Dermatology Procedures Equipment segment the Company sells its products internationally through distributors and domestically, directly to a physician. For the product sales, the Company recognizes revenues when control of the promised products is transferred to either the Company's distributors or end-user customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products (the transaction price). Control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment and legal title must have passed to the customer. The Company ships most of its products FOB shipping point, and as such, the Company primarily transfers control and records revenue upon shipment. From time to time the Company will grant certain customers, for example governmental customers, FOB destination terms, and the transfer of control for revenue recognition occurs upon receipt. The Company has elected to recognize the cost of freight and shipping activities as fulfillment costs. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenues.

Remaining performance obligations related to ASC 606 represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year, which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include the potential obligation to perform under extended warranties but excludes any equipment accounted for as leases. As of March 31, 2020, the aggregate amount of the transaction price allocated to remaining performance obligations was $267, and the Company expects to recognize $186 of the remaining performance obligations within one year and the remainder over one to three years. Contract assets primarily relate to the Company’s rights to consideration for work completed in relation to its services performed but not billed at the reporting date. The contract assets are transferred to receivables when the rights become unconditional. Currently, the Company does not have any contract assets which have not transferred to a receivable. Contract liabilities primarily relate to extended warranties where the Company has received payments, but has not yet satisfied the related performance obligations. The allocations of the transaction price are based on the price of stand-alone warranty contracts sold in the ordinary course of business. The advance consideration received from customers for the warranty services is a contract liability that is recognized ratably over the warranty period. As of March 31, 2020, the $186 of short-term contract liabilities is presented as deferred revenues and the $81 of long-term contract liabilities is presented within Other Liabilities on the Condensed Consolidated Balance Sheet. For the three months ended March 31, 2020, the Company recognized $57 as revenue from amounts classified as contract liabilities (i.e. deferred revenues), as of December 31, 2019.

With respect to contract acquisition costs, the Company applied the practical expedient and expenses these costs immediately.

The Company records co-pay reimbursements made to patients receiving laser treatments as a reduction of revenue. For the three months ended March 31, 2020, and 2019, the Company recorded such reimbursements in the amounts of $168 and $155, respectively.

The following tables present the Company’s revenue disaggregated by geographical region for the three months ended March 31, 2020 and, 2019, respectively. Domestic refers to revenue from customers based in the United States, and substantially all foreign revenue is derived from dermatology procedures equipment sales to the Company’s international master distributor for physicians based primarily in Asia and recurring revenue from our distributor in Korea.

	Three Months Ended March 31, 2020
	Dermatology Recurring Procedures		Dermatology Procedures Equipment		TOTAL
Domestic	$	5,597	$	315	$	5,912
Foreign		104		714		818
Total	$	5,701	$	1,029	$	6,730

	Three Months Ended March 31, 2019
	Dermatology Recurring Procedures		Dermatology Procedures Equipment		TOTAL
Domestic	$	5,312	$	324	$	5,636
Foreign		-		1,847		1,847
Total	$	5,312	$	2,171	$	7,483

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international recurring revenue customers as of March 31,

Remaining 2020	$	365
2021		413
2022		413
2023		340
2024		126
Thereafter		-
Total	$	1,657

Inventories

3 Months Ended

Mar. 31, 2020

Inventories [Abstract]

Inventories

Note 4

Inventories:

Inventories consist of:

	March 31, 2020		December 31, 2019
Raw materials and work-in-process	$	2,813	$	2,651
Finished goods		658		376
Total inventories	$	3,471	$	3,027

Work-in-process is immaterial, given the Company’s typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.

Property and Equipment, net

3 Months Ended

Mar. 31, 2020

Property and Equipment, net [Abstract]

Property and Equipment, net

Note 5

Property and Equipment, net:

Property and equipment consist of:

	March 31, 2020			December 31, 2019
Lasers placed-in-service	$	21,511		$	20,925
Equipment, computer hardware and software		146			146
Furniture and fixtures		234			234
Leasehold improvements		26			26
		21,917			21,331
Accumulated depreciation and amortization		(16,538	)		(15,962	)
Property and equipment, net	$	5,379		$	5,369

Depreciation and related amortization expense was $586 and $751 for the three months ended March 31, 2020 and 2019, respectively.

Intangible Assets, net

3 Months Ended

Mar. 31, 2020

Intangible Assets, net [Abstract]

Intangible Assets, net

Note 6

Intangible Assets, net:

Set forth below is a detailed listing of definite-lived intangible assets as of March 31, 2020:

	Balance		Accumulated Amortization			Intangible assets, net
Core technology	$	5,700	$	(2,708	)	$	2,992
Product technology		2,000		(1,900	)		100
Customer relationships		6,900		(3,277	)		3,623
Tradenames		1,500		(712	)		788
	$	16,100	$	(8,597	)	$	7,503

Related amortization expense was $452 and $453 for the three months ended March 31, 2020 and, 2019, respectively.

Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset group may not be recoverable. The Company recognizes an impairment loss when and to the extent that the recoverable amount of an asset group is less than its carrying value. There were no impairment charges for the three months ended March 31, 2020.

Estimated amortization expense for the above amortizable intangible assets for future periods is as follows:

Remaining 2020	$	1,158
2021		1,410
2022		1,410
2023		1,410
2024		1,410
2025		705
Total	$	7,503

Other Accrued Liabilities

3 Months Ended

Mar. 31, 2020

Other Accrued Liabilities [Abstract]

Other Accrued Liabilities

Note 7

Other Accrued Liabilities:

Other accrued liabilities consist of:

	March 31, 2020		December 31, 2019

Accrued warranty, current	$	143	$	170
Accrued compensation, including commissions and vacation		1,258		1,193
Accrued state sales, use and other taxes		3,191		3,193
Accrued professional fees and other accrued liabilities		558		578
Total other accrued liabilities	$	5,150	$	5,134

Accrued State Sales and Use Tax

In the ordinary course of business, the Company is subject to audits performed by state taxing authorities. These actions and proceedings are generally based on the position that the arrangements entered into by the Company are subject to sales and use tax rather than exempt from tax under applicable law. The Company uses estimates when accruing its sales and use tax liability and all of the Company’s tax positions are subject to audit. One state has assessed the Company an amount of $801 for the period from March 2014 through August 2017. The Company has declined an informal offer to settle at a substantially lower amount and is currently in that jurisdiction’s administrative process of appeal. A second jurisdiction has made an assessment of $720 from June 2015 through March 2018 plus interest of $171 through April 2020. The Company is currently also in that jurisdiction’s administrative process of appeal. If there is a determination that the true object of the Company’s recurring revenue model is not exempt from sales taxes and is not equivalent to prescription medicine or the Company does not have other defenses where the Company does not prevail, the Company may be subject to sales taxes in those particular states for previous years and in the future, plus potential interest and penalties for failure to pay such taxes.

The Company believes its state sales and use tax accruals have properly recognized such that if the Company’s arrangements with customers are deemed more likely than not that the Company would not be exempt from sales tax in a particular state the basis for measurement of the state sales and use tax is calculated in accordance with ASC 405, Liabilities as a transaction tax. If and when the Company is successful in defending itself or in settling the sales tax obligation for a lesser amount, the reversal of this liability is to be recorded in the period the settlement is reached. However, the precise scope, timing and time period at issue, as well as the final outcome of any audit and actual settlement remains uncertain.

The Company records state sales tax collected and remitted for its customers on equipment sales on a net basis, excluded from revenue. The Company’s sales tax expense that is not presently being collected and remitted for the recurring revenue business are recorded in general and administrative expenses on the condensed consolidated statements of operations.

Accrued Warranty Costs

The Company offers a standard warranty on product sales generally for a one to two-year period, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold. Total accrued warranty is included in other accrued liabilities and other liabilities on the condensed consolidated balance sheet. The activity in the warranty accrual during the three months ended March 31, 2020 and, 2019, is summarized as follows:

	Three Months Ended, March 31,
	2020			2019
Accrual at beginning of period	$	232		$	238
Additions charged to warranty expense		3			68
Expiring warranties/claimed satisfied		(54	)		(34	)
Total		181			272
Less: current portion		(143	)		(183	)
Total long-term accrued warranty costs	$	38		$	89

Note Payable	3 Months Ended
Note Payable	Mar. 31, 2020
Note Payable [Abstract]
Note Payable	Note 8 Note Payable On December 30, 2019, the Company closed on a $7,275 loan with a commercial bank pursuant to a one-year Fixed Rate – Term Promissory Note (the “Note”). The Company's obligations under the Note are secured by an Assignment and Pledge of Time Deposit (the “Agreement”), under which the Company has pledged to the commercial bank the proceeds of a time deposit account in the amount of the loan and recorded the time deposit and accrued interest as restricted cash on the balance sheet. The principal is due on December 30, 2020 with no penalties for prepayments. The interest rate is fixed at 2.79%. The secured time deposit has a fixed interest rate of 1.79%. The Company concurrently fully repaid (including payment of termination and exit fees) its then existing long-term debt credit facility with Midcap Financial Trust (“MidCap”). The transaction was accounted for as a debt extinguishment.

Long-term Debt	3 Months Ended
Long-term Debt	Mar. 31, 2020
Long-term Debt [Abstract]
Long-term Debt	Note 9 Long-term Debt: Term-Note Credit Facility On December 30, 2015, the Company entered into a $12,000 credit facility pursuant to a Credit and Security Agreement (the "Credit Agreement") and related financing documents with MidCap and the lenders listed therein. Under the Credit Agreement, the credit facility could be drawn down in two tranches, the first of which was drawn for $10,500 on December 30, 2015. The second tranche was drawn for $1,500 on January 29, 2016. The maturity date of the credit facility was December 1, 2020. The Company's obligations under the credit facility were secured by a first priority lien on all the Company's assets. This credit facility had an interest rate of one-month LIBOR plus 8.25% and included both financial and non-financial covenants, including a minimum net revenue covenant. On November 10, 2017, the minimum net revenue covenant was amended prospectively and there was an increase in the exit fee. Additionally, on November 10, 2017, the Company entered into an amendment to modify the principal payments including a period of six months where there are no principal payments due. On March 26, 2018, the Company entered into a Third Amendment to the Credit Agreement with MidCap. For the period beginning on the closing date of the loan and ending on January 31, 2018, the gross revenue in accordance with U.S. GAAP for the twelve-month period ending on the last day of the most recently completed calendar month was amended to be less than the minimum amount on the Covenant Schedule, as defined in the Credit Agreement. This amendment waived the event of default related to the revenue covenant for the period ending February 2018. This amendment also amended the monthly net revenue covenant. On May 29, 2018, the Company entered into a Fourth Amendment to Credit Agreement (the “Amendment”), pursuant to which the Company repaid $3,000 in principal of then existing $10,571 credit facility. The terms of the credit facility were amended to impose less restrictive covenants and lower prepayment fees for the Company and extended the maturity date to May 2022. The Amendment modified the principal payments including a period of 18 months where there are no principal payments due. Principal payments beginning December 2019 were $252 plus interest per month. The interest rate on the credit facility was one-month LIBOR plus 7.25%. The Company was in compliance with all covenants as of December 31, 2018. On April 30, July 15, August 26, and October 15, 2019, the Company received waivers from Midcap as administrative agent for the lenders who are party to the Agreement, wherein the lenders waived the Company’s compliance with the obligation to deliver audited financial statements within 120 days of year-end pursuant to the Credit Agreement. The waivers were effective through November 7, 2019. The Company delivered the audited financial statements on or about October 29, 2019 to cure the event of default. These amendments had been accounted for as debt modifications as the present value of the cash flows changed by less than 10%. All borrowings under the Credit Facility were fully repaid in connection with the execution of a Fixed Rate-Promissory Note on December 30, 2019.

Warrants

3 Months Ended

Mar. 31, 2020

Warrants [Abstract]

Warrants

Note 10

Warrants:

The Company accounts for warrants that require net cash settlement upon change of control of the Company as liabilities instead of equity. During the three months ended March 31, 2019, warrants to purchase 265,947 and 137,143 shares of common stock each with an exercise price of $3.75 per share were accounted for as derivatives. These warrants expired on February 5, 2019 and April 30, 2019, respectively. These derivatives had de minimus fair values as of March 31, 2019.

Outstanding common stock warrants at March 31, 2020 consist of the following:

Issue Date	Expiration Date	Total Warrants		Exercise Price
June 22, 2015	June 22, 2020		600,000	$	3.75
December 30, 2015	December 30, 2020		130,089	$	5.65
January 29, 2016	January 29, 2021		19,812	$	5.30
			749,901

Stock-based Compensation	3 Months Ended
Stock-based Compensation	Mar. 31, 2020
Stock-based Compensation [Abstract]
Stock-based Compensation	Note 11 Stock-based Compensation: As of March 31, 2020, the Company had options to purchase 4,908,038 shares of common stock outstanding with a weighted-average exercise price of $1.90. As of March 31, 2020, options to purchase 2,036,577 shares are vested and exercisable. There are 432,774 shares remaining available for issuance in the form of future equity awards as of March 31, 2020. There were 169,023 restricted stock units outstanding as of March 31, 2020. Stock-based compensation expense, which is included in general and administrative expense, for the three months ended March 31, 2020 and 2019, was $430 and $323, respectively. As of March 31, 2020, there was $2,442 in unrecognized compensation expense, which will be recognized over a weighted average period of 1.05 years.

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2020
Income Taxes [Abstract]
Income Taxes	Note 12 Income Taxes: The Company accounts for income taxes using the asset and liability method for deferred income taxes. The provision for income taxes includes federal, state and local income taxes currently payable and deferred taxes resulting from temporary differences between the financial statement and tax bases of assets and liabilities. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Income tax expense of $88 and benefit of $43 for the three months ended March 31, 2020 and, 2019, respectively, was comprised primarily changes in deferred tax liability related to goodwill. Goodwill is an amortizing asset according to tax regulations. The United States enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). The CARES Act is an approximately $2 trillion emergency economic stimulus package in response to the COVID-19 outbreak, which among other things contains numerous income tax provisions. Some of these tax provisions are expected to be effective retroactively for years ending before the date of enactment. The Company analyzed the impact of the CARES Act and does not foresee a significant impact on its condensed consolidated financial position, results of operations, effective tax rate and cash flows. The Company has experienced certain ownership changes, which under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, result in annual limitations on the Company's ability to utilize its net operating losses in the future. The February 2014, July 2014, June 2015 and May 2018 equity raises by the Company will limit the annual use of these net operating loss carryforwards. Although the Company has not performed a Section 382 study, any limitation of its pre-change net operating loss carryforwards that would result in a reduction of its deferred tax asset would also have an equal and offsetting adjustment to the valuation allowance.

Business Segments

3 Months Ended

Mar. 31, 2020

Business Segments [Abstract]

Business Segments

Note 13

Business Segments:

The Company has organized its business into two operating segments to present its organization based upon the Company’s management structure, products and services offered, markets served and types of customers, as follows: The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance.

Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest expense and other income (expense), net, are also not allocated to the operating segments.

The following tables reflect results of operations from our business segments for the periods indicated below:

Three Months Ended March 31, 2020

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			TOTAL
Revenues	$	5,701		$	1,029		$	6,730
Costs of revenues		1,802			529			2,331
Gross profit		3,899			500			4,399
Gross profit %		68.4	%		48.6	%		65.4	%

Allocated operating expenses:
Engineering and product development		274			18			292
Selling and marketing		2,797			156			2,953

Unallocated operating expenses		-			-			2,102
		3,071			174			5,347
Income (loss) from operations		828			326			(948	)

Interest income, net		-			-			1

Income (loss) before income taxes	$	828		$	326		$	(947	)

Three Months Ended March 31, 2019

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			TOTAL
Revenues	$	5,312		$	2,171		$	7,483
Costs of revenues		1,793			1,081			2,874
Gross profit		3,519			1,090			4,609
Gross profit %		66.2	%		50.2	%		61.6	%

Allocated operating expenses:
Engineering and product development		242			62			304
Selling and marketing		2,768			298			3,066

Unallocated operating expenses		-			-			2,480
		3,010			360			5,850
Income (loss) from operations		509			730			(1,241	)

Interest expense, net		-			-			(135	)

Income (loss) before income taxes	$	509		$	730		$	(1,376	)

Significant Customer Concentration	3 Months Ended
Significant Customer Concentration	Mar. 31, 2020
Significant Customer Concentration [Abstract]
Significant Customer Concentration	Note 14 Significant Customer Concentration: For the three months ended March 31, 2019, revenues from sales to the Company’s international master distributor (GlobalMed Technologies) were $1,990, or 27%, of total revenues for such period. No other customer represented more than 10% of total company revenues for the three months ended March 31, 2020 and 2019. No customer represented more than 10% of total accounts receivable as of March 31, 2020.

Commitments

3 Months Ended

Mar. 31, 2020

Commitments [Abstract]

Commitments

Note 15

Commitments:

Leases

The Company recognizes right-of-use assets (“ROU assets”) and operating lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company adopted the short-term accounting election for leases with a duration of less than one year. The Company leases its facilities and certain IT and office equipment under non-cancellable operating leases. All of the Company's leasing arrangements are classified as operating leases with remaining lease terms ranging from 1 to 5 years, and one facility lease has a renewal option for two years. Renewal options have been excluded from the determination of the lease term as they are not reasonably certain of exercise. The Company entered into an addendum with FR National Life, LLC for the Carlsbad facility. The extension began on October 1, 2019 for five years and was executed on May 1, 2019. Included in cash flows provided by operations for the three months ended March 31, 2020 and, 2019, there was amortization of right-of-use assets of $79 and $93, respectively.

Operating lease costs were $112 and $111 for the three months ended March 31, 2020 and, 2019, respectively. Cash paid for amounts included in the measurement of operating lease liabilities was $93 and $94 for the three months ended March 31, 2020 and, 2019, respectively. As of March 31, 2020, the incremental borrowing rate was 9.76 % and the weighted average remaining lease term was 3.9 years. The following table summarizes the Company’s operating lease maturities as of March 31, 2020:

For the year ending December 31,	Amount
Remaining 2020	$	343
2021		456
2022		371
2023		242
2024		186
Total remaining lease payments		1,598
Less: imputed interest		(267	)
Total lease liabilities	$	1,331

Contingencies:

In the ordinary course of business, the Company is routinely defendants in or parties to pending and threatened legal actions and proceedings, including actions brought on behalf of various classes of claimants. These actions and proceedings are generally based on alleged violations of employment, contract and other laws. In some of these actions and proceedings, claims for substantial monetary damages are asserted against the Company. In the ordinary course of business, the Company is also subject to regulatory and governmental examinations, information gathering requests, inquiries, investigations, and threatened legal actions and proceedings. In connection with formal and informal inquiries by federal, state, local and foreign agencies, the Company receives numerous requests, subpoenas and orders for documents, testimony and information in connection with various aspects of its activities.

Subsequent Event	3 Months Ended
Subsequent Event	Mar. 31, 2020
Subsequent Event [Abstract]
Subsequent Event	Note 16 Subsequent event In April 2020, in response to the ongoing COVID-19 pandemic and as part of broader actions taken by the Company to reduce operating expenses and conserve cash resources, the Company announced expense reductions including furloughing employees, temporarily deferring executive bonuses and Board of Directors fees and reducing all discretionary spending including direct to patient marketing. On April 22, 2020, the Company closed a loan of $2,028 (the “PPP loan”) from a commercial bank, pursuant to the Paycheck Protection Program (“PPP”) administered by the Small Business Administration (the “SBA”) pursuant to the CARES Act. The PPP loan matures on May 1, 2022 and bears an interest rate of 1% per annum. Payments of principal and interest of any unforgiven balance commence December 1, 2020. All or a portion of the PPP loan may be forgiven by the lender upon application by the Company beginning 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the requirements set forth by the SBA pursuant to the CARES Act. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the eight-week period beginning on the date of disbursement of proceeds from the PPP loan. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 25% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25%. In the event the PPP loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal.

The Company (Policies)

3 Months Ended

Mar. 31, 2020

The Company [Abstract]

Principles of Consolidation

Unaudited Interim Condensed Consolidated Financial Statements

Reclassifications

Significant Accounting Policies

Use of Estimates

Fair Value Measurements

	•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
	•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
	•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors.

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

Earnings Per Share

The following table presents the calculation of basic and diluted loss per share by each class of security for the three months ended March 31, 2020 and, 2019:

	Three Months Ended March 31, 2020						Three Months Ended March 31, 2019
	Common Stock			Series C Convertible Preferred Stock			Common Stock			Series C Convertible Preferred Stock

Loss attributable to each class	$	(1,018	)	$	(17	)	$	(1,216	)	$	(117	)

Weighted average number of shares outstanding during the period		33,164,321			1,480			30,703,501			7,944

Basic and Diluted loss per share	$	(0.03	)	$	(11.42	)	$	(0.04	)	$	(14.72	)

	Three Months Ended March 31,
	2020		2019
Common stock purchase warrants		749,901		2,233,192
Restricted stock units		169,023		129,576
Common stock options		4,908,038		4,321,932
Total		5,826,962		6,684,700

Accounting Pronouncements Recently Adopted and Not Yet Adopted

Accounting Pronouncements Recently Adopted

Recent Accounting Pronouncements Not Yet Adopted

The Company (Tables)

3 Months Ended

Mar. 31, 2020

The Company [Abstract]

Calculation of Basic and Diluted Loss Per Share by Class of Security

The following table presents the calculation of basic and diluted loss per share by each class of security for the three months ended March 31, 2020 and, 2019:

	Three Months Ended March 31, 2020						Three Months Ended March 31, 2019
	Common Stock			Series C Convertible Preferred Stock			Common Stock			Series C Convertible Preferred Stock

Loss attributable to each class	$	(1,018	)	$	(17	)	$	(1,216	)	$	(117	)

Weighted average number of shares outstanding during the period		33,164,321			1,480			30,703,501			7,944

Basic and Diluted loss per share	$	(0.03	)	$	(11.42	)	$	(0.04	)	$	(14.72	)

Antidilutive Securities Excluded from Computation of Earnings Per Share

	Three Months Ended March 31,
	2020		2019
Common stock purchase warrants		749,901		2,233,192
Restricted stock units		169,023		129,576
Common stock options		4,908,038		4,321,932
Total		5,826,962		6,684,700

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2020

Revenue Recognition [Abstract]

Disaggregation of Revenue

	Three Months Ended March 31, 2020
	Dermatology Recurring Procedures		Dermatology Procedures Equipment		TOTAL
Domestic	$	5,597	$	315	$	5,912
Foreign		104		714		818
Total	$	5,701	$	1,029	$	6,730

	Three Months Ended March 31, 2019
	Dermatology Recurring Procedures		Dermatology Procedures Equipment		TOTAL
Domestic	$	5,312	$	324	$	5,636
Foreign		-		1,847		1,847
Total	$	5,312	$	2,171	$	7,483

Future Undiscounted Fixed Treatment Code Payments from International Recurring Revenue Customers

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international recurring revenue customers as of March 31,

Remaining 2020	$	365
2021		413
2022		413
2023		340
2024		126
Thereafter		-
Total	$	1,657

Inventories (Tables)

3 Months Ended

Mar. 31, 2020

Inventories [Abstract]

Inventories

Inventories consist of:

	March 31, 2020		December 31, 2019
Raw materials and work-in-process	$	2,813	$	2,651
Finished goods		658		376
Total inventories	$	3,471	$	3,027

Property and Equipment, net (Tables)

3 Months Ended

Mar. 31, 2020

Property and Equipment, net [Abstract]

Property and Equipment, Net

Property and equipment consist of:

	March 31, 2020			December 31, 2019
Lasers placed-in-service	$	21,511		$	20,925
Equipment, computer hardware and software		146			146
Furniture and fixtures		234			234
Leasehold improvements		26			26
		21,917			21,331
Accumulated depreciation and amortization		(16,538	)		(15,962	)
Property and equipment, net	$	5,379		$	5,369

Intangible Assets, net (Tables)

3 Months Ended

Mar. 31, 2020

Intangible Assets, net [Abstract]

Definite-lived Intangible Assets

Set forth below is a detailed listing of definite-lived intangible assets as of March 31, 2020:

	Balance		Accumulated Amortization			Intangible assets, net
Core technology	$	5,700	$	(2,708	)	$	2,992
Product technology		2,000		(1,900	)		100
Customer relationships		6,900		(3,277	)		3,623
Tradenames		1,500		(712	)		788
	$	16,100	$	(8,597	)	$	7,503

Finite-lived Intangible Assets Amortization Expense

Estimated amortization expense for the above amortizable intangible assets for future periods is as follows:

Remaining 2020	$	1,158
2021		1,410
2022		1,410
2023		1,410
2024		1,410
2025		705
Total	$	7,503

Other Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2020

Other Accrued Liabilities [Abstract]

Other Accrued Liabilities

Other accrued liabilities consist of:

	March 31, 2020		December 31, 2019

Accrued warranty, current	$	143	$	170
Accrued compensation, including commissions and vacation		1,258		1,193
Accrued state sales, use and other taxes		3,191		3,193
Accrued professional fees and other accrued liabilities		558		578
Total other accrued liabilities	$	5,150	$	5,134

Accrued Warranty Costs Activity

The activity in the warranty accrual during the three months ended March 31, 2020 and, 2019, is summarized as follows:

	Three Months Ended, March 31,
	2020			2019
Accrual at beginning of period	$	232		$	238
Additions charged to warranty expense		3			68
Expiring warranties/claimed satisfied		(54	)		(34	)
Total		181			272
Less: current portion		(143	)		(183	)
Total long-term accrued warranty costs	$	38		$	89

Warrants (Tables)

3 Months Ended

Mar. 31, 2020

Warrants [Abstract]

Outstanding Common Stock Warrants

Outstanding common stock warrants at March 31, 2020 consist of the following:

Issue Date	Expiration Date	Total Warrants		Exercise Price
June 22, 2015	June 22, 2020		600,000	$	3.75
December 30, 2015	December 30, 2020		130,089	$	5.65
January 29, 2016	January 29, 2021		19,812	$	5.30
			749,901

Business Segments (Tables)

3 Months Ended

Mar. 31, 2020

Business Segments [Abstract]

Segment Reporting Information by Segment

The following tables reflect results of operations from our business segments for the periods indicated below:

Three Months Ended March 31, 2020

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			TOTAL
Revenues	$	5,701		$	1,029		$	6,730
Costs of revenues		1,802			529			2,331
Gross profit		3,899			500			4,399
Gross profit %		68.4	%		48.6	%		65.4	%

Allocated operating expenses:
Engineering and product development		274			18			292
Selling and marketing		2,797			156			2,953

Unallocated operating expenses		-			-			2,102
		3,071			174			5,347
Income (loss) from operations		828			326			(948	)

Interest income, net		-			-			1

Income (loss) before income taxes	$	828		$	326		$	(947	)

Three Months Ended March 31, 2019

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			TOTAL
Revenues	$	5,312		$	2,171		$	7,483
Costs of revenues		1,793			1,081			2,874
Gross profit		3,519			1,090			4,609
Gross profit %		66.2	%		50.2	%		61.6	%

Allocated operating expenses:
Engineering and product development		242			62			304
Selling and marketing		2,768			298			3,066

Unallocated operating expenses		-			-			2,480
		3,010			360			5,850
Income (loss) from operations		509			730			(1,241	)

Interest expense, net		-			-			(135	)

Income (loss) before income taxes	$	509		$	730		$	(1,376	)

Commitments (Tables)

3 Months Ended

Mar. 31, 2020

Commitments [Abstract]

Operating Leases Maturities

The following table summarizes the Company’s operating lease maturities as of March 31, 2020:

For the year ending December 31,	Amount
Remaining 2020	$	343
2021		456
2022		371
2023		242
2024		186
Total remaining lease payments		1,598
Less: imputed interest		(267	)
Total lease liabilities	$	1,331

The Company, Background (Details) $ in Thousands	3 Months Ended
The Company, Background (Details) $ in Thousands	Mar. 31, 2020 USD ($) Extension
Finite-Lived Intangible Assets, Net [Abstract]
Delayed payments to vendors \| $	$ 400
South Korea [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Term of distribution agreement	12 months
Number of extensions of agreement \| Extension	4

The Company, Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Loss attributable to each class	$ (1,018)	$ (1,216)
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	5,826,962	6,684,700
Series C Preferred Stock [Member]
Earnings Per Share [Abstract]
Loss attributable to each class	$ (17)	$ (117)
Weighted average number of shares outstanding during the period (in shares)	1,480	7,944
Basic and diluted loss per share (in dollars per share)	$ (11.42)	$ (14.72)
Common Stock [Member]
Earnings Per Share [Abstract]
Loss attributable to each class	$ (1,018)	$ (1,216)
Weighted average number of shares outstanding during the period (in shares)	33,164,321	30,703,501
Basic and diluted loss per share (in dollars per share)	$ (0.03)	$ (0.04)
Common Stock Purchase Warrants [Member]
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	749,901	2,233,192
Restricted Stock Units [Member]
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	169,023	129,576
Common Stock Options [Member]
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	4,908,038	4,321,932

Revenue Recognition, Remaining Performance Obligation (Details) $ in Thousands	Mar. 31, 2020 USD ($)
Remaining Performance Obligation [Abstract]
Remaining performance obligations	$ 267
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Remaining Performance Obligation [Abstract]
Remaining performance obligations	$ 186
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 \| Minimum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 \| Maximum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period	3 years

Revenue Recognition, Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Treatment Equipment [Abstract]
Lease term	36 months
Contract with Customer, Liability [Abstract]
Short-term contract liabilities	$ 186
Long-term contract liabilities	81
Change in Contract with Customer, Liability [Abstract]
Contract liabilities recognized as revenue	57
Co-pay reimbursements recorded as reduction of revenue	$ (168)	$ (155)
Minimum [Member]
Treatment Equipment [Abstract]
Notice period to cancel contract agreement	30 days
Maximum [Member]
Treatment Equipment [Abstract]
Notice period to cancel contract agreement	60 days
South Korea [Member]
Treatment Equipment [Abstract]
Lease term	48 months

Revenue Recognition, Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Abstract]
Revenues, net	$ 6,730	$ 7,483
Dermatology Recurring Procedures [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	5,701	5,312
Dermatology Procedures Equipment [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	1,029	2,171
Domestic [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	5,912	5,636
Domestic [Member] \| Dermatology Recurring Procedures [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	5,597	5,312
Domestic [Member] \| Dermatology Procedures Equipment [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	315	324
Foreign [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	818	1,847
Foreign [Member] \| Dermatology Recurring Procedures [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	104	0
Foreign [Member] \| Dermatology Procedures Equipment [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	$ 714	$ 1,847

Revenue Recognition, Future Undiscounted Fixed Payments from International Recurring Revenue Customers (Details) $ in Thousands	Mar. 31, 2020 USD ($)
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 267
International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	1,657
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 186
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 365
Expected timing of satisfaction period	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 413
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 413
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 340
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 126
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 0
Expected timing of satisfaction period

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Schedule of inventory [Abstract]
Raw materials and work-in-process	$ 2,813	$ 2,651
Finished goods	658	376
Total inventories	$ 3,471	$ 3,027

Property and Equipment, net (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	$ 21,917		$ 21,331
Accumulated depreciation and amortization	(16,538)		(15,962)
Property and equipment, net	5,379		5,369
Depreciation and related amortization expense	586	$ 751
Lasers Placed-In-Service [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	21,511		20,925
Equipment, Computer Hardware and Software [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	146		146
Furniture and Fixtures [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	234		234
Leasehold Improvements [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	$ 26		$ 26

Intangible Assets, net (Details) - USD ($) $ in Thousands	3 Months Ended
Intangible Assets, net (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Finite-Lived Intangible Assets, Net [Abstract]
Balance	$ 16,100
Accumulated amortization	(8,597)
Intangible assets, net	7,503
Amortization expense of intangible assets	452	$ 453
Impairment of intangible assets	0
Estimated amortization expense [Abstract]
Remaining 2020	1,158
2021	1,410
2022	1,410
2023	1,410
2024	1,410
2025	705
Intangible assets, net	7,503
Core Technology [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Balance	5,700
Accumulated amortization	(2,708)
Intangible assets, net	2,992
Estimated amortization expense [Abstract]
Intangible assets, net	2,992
Product Technology [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Balance	2,000
Accumulated amortization	(1,900)
Intangible assets, net	100
Estimated amortization expense [Abstract]
Intangible assets, net	100
Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Balance	6,900
Accumulated amortization	(3,277)
Intangible assets, net	3,623
Estimated amortization expense [Abstract]
Intangible assets, net	3,623
Tradenames [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Balance	1,500
Accumulated amortization	(712)
Intangible assets, net	788
Estimated amortization expense [Abstract]
Intangible assets, net	$ 788

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Other Accrued Liabilities [Abstract]
Accrued warranty, current	$ 143	$ 170	$ 183
Accrued compensation, including commissions and vacation	1,258	1,193
Accrued state sales, use and other taxes	3,191	3,193
Accrued professional fees and other accrued liabilities	558	578
Total other accrued liabilities	5,150	$ 5,134
Income Tax Examination, Penalties and Interest Accrued [Abstract]
Estimated tax positions subject to audit	801
Assessment amount	720
Interest amount	$ 171

Other Accrued Liabilities, Accrued Warranty Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Product Warranty Accrual [Roll Forward]
Accrual at beginning of period	$ 232	$ 238
Additions charged to warranty expense	3	68
Expiring warranties/claims satisfied	(54)	(34)
Total	181	272
Less: current portion	(143)	(183)	$ (170)
Total long-term accrued warranty costs	$ 38	$ 89
Minimum [Member]
Accrued warranty costs [Abstract]
Standard warranty period	1 year
Offered warranty period	3 years
Maximum [Member]
Accrued warranty costs [Abstract]
Standard warranty period	2 years
Offered warranty period	4 years

Note Payable (Details) - USD ($) $ in Thousands	3 Months Ended
Note Payable (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 30, 2019
Note [Member]
Debt Instruments [Abstract]
Face amount of debt		$ 7,275
Debt instrument term	1 year
Maturity date	Dec. 30, 2020
Fixed interest rate		2.79%
Time Deposit [Member]
Debt Instruments [Abstract]
Fixed interest rate		1.79%

Long-term Debt (Details) - MidCap Financial Trust [Member] - Term-Note Credit Facility [Member] $ in Thousands				3 Months Ended
	May 29, 2018 USD ($)	Jan. 29, 2016 USD ($)	Dec. 30, 2015 USD ($) Tranche	Mar. 31, 2020 USD ($)
Line of Credit Facility [Line Items]
Maximum borrowing capacity under the agreement			$ 12,000
Number of tranches \| Tranche			2
Repayment of debt	$ (3,000)
Maturity date				May 31, 2022
Credit facility amount outstanding	$ 10,571
Period without debt principal payments due				18 months
Monthly payment, principal				$ 252
Percentage of change in cash flows, due to debt modifications	10.00%
LIBOR [Member]
Line of Credit Facility [Line Items]
Debt instrument term of variable rate			1 month	1 month
Debt instrument variable rate			8.25%	7.25%
First Tranche [Member]
Line of Credit Facility [Line Items]
Proceeds from credit facility			$ 10,500
Second Tranche [Member]
Line of Credit Facility [Line Items]
Proceeds from credit facility		$ 1,500

Warrants (Details) - $ / shares	3 Months Ended
Warrants (Details) - $ / shares	Mar. 31, 2020	Mar. 31, 2019
Warrants and Rights [Abstract]
Total Warrants (in shares)	749,901
Expiration Date, February 5, 2019 [Member]
Warrants and Rights [Abstract]
Number of shares underlying warrants (in shares)		265,947
Exercise price (in dollars per share)		$ 3.75
Expiration Date, April 30, 2019 [Member]
Warrants and Rights [Abstract]
Number of shares underlying warrants (in shares)		137,143
Exercise price (in dollars per share)		$ 3.75
Expiration Date, June 22, 2020 [Member]
Warrants and Rights [Abstract]
Issue date	Jun. 22, 2015
Expiration date	Jun. 22, 2020
Total Warrants (in shares)	600,000
Exercise price (in dollars per share)	$ 3.75
Expiration Date, December 30, 2020 [Member]
Warrants and Rights [Abstract]
Issue date	Dec. 30, 2015
Expiration date	Dec. 30, 2020
Total Warrants (in shares)	130,089
Exercise price (in dollars per share)	$ 5.65
Expiration Date, January 29, 2021 [Member]
Warrants and Rights [Abstract]
Issue date	Jan. 29, 2016
Expiration date	Jan. 29, 2021
Total Warrants (in shares)	19,812
Exercise price (in dollars per share)	$ 5.30

Stock-based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Additional General Disclosures [Abstract]
Stock-based compensation expense	$ 430	$ 323
Compensation Cost Not yet Recognized [Abstract]
Unrecognized compensation expense	$ 2,442
Weighted average period of recognition	1 year 18 days
Stock Options [Member]
Number of Stock Options [Abstract]
Options outstanding (in shares)	4,908,038
Weighted average exercise price, outstanding (in dollars per share)	$ 1.90
Vested (in shares)	2,036,577
Exercisable (in shares)	2,036,577
Number of shares available for issuance (in shares)	432,774
Restricted Stock Units [Member] \| Members of the Board of Directors [Member]
Restricted Stock Units [Abstract]
Restricted stock units outstanding (in shares)	169,023

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Income Taxes [Abstract]
Income tax (benefit)	$ 88	$ (43)

Business Segments (Details) $ in Thousands	3 Months Ended
Business Segments (Details) $ in Thousands	Mar. 31, 2020 USD ($) Segment	Mar. 31, 2019 USD ($)
Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]
Number of operating segments \| Segment	2
Results of Operations from Business Segments [Abstract]
Revenues	$ 6,730	$ 7,483
Cost of revenues	2,331	2,874
Gross profit	$ 4,399	$ 4,609
Gross profit %	65.40%	61.60%
Allocated operating expenses [Abstract]
Engineering and product development	$ 292	$ 304
Selling and marketing	2,953	3,066
Unallocated operating expenses	2,102	2,480
Total operating expenses	5,347	5,850
Loss from operations	(948)	(1,241)
Interest income (expense), net	1	(135)
Loss before income taxes	(947)	(1,376)
Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	5,701	5,312
Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	1,029	2,171
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	5,701	5,312
Cost of revenues	1,802	1,793
Gross profit	$ 3,899	$ 3,519
Gross profit %	68.40%	66.20%
Allocated operating expenses [Abstract]
Engineering and product development	$ 274	$ 242
Selling and marketing	2,797	2,768
Unallocated operating expenses	0	0
Total operating expenses	3,071	3,010
Loss from operations	828	509
Interest income (expense), net	0	0
Loss before income taxes	828	509
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	1,029	2,171
Cost of revenues	529	1,081
Gross profit	$ 500	$ 1,090
Gross profit %	48.60%	50.20%
Allocated operating expenses [Abstract]
Engineering and product development	$ 18	$ 62
Selling and marketing	156	298
Unallocated operating expenses	0	0
Total operating expenses	174	360
Loss from operations	326	730
Interest income (expense), net	0	0
Loss before income taxes	$ 326	$ 730

Significant Customer Concentration (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Concentration Risk Percentage [Abstract]
Revenues, net	$ 6,730	$ 7,483
Revenue [Member] \| Customer Concentration Risk [Member]
Concentration Risk Percentage [Abstract]
Revenues, net	$ 1,990
Concentration risk percentage	27.00%

Commitments (Details) - USD ($) $ in Thousands	3 Months Ended
Commitments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Lessee, Operating Lease, Description [Abstract]
Amortization of right-of-use assets	$ 79	$ 93
Operating lease costs	112	111
Cash paid for amounts included in measurement of operating lease liabilities	$ 93	$ 94
Incremental borrowing rate	9.76%
Weighted average remaining lease term	3 years 10 months 24 days
Operating Lease Maturities [Abstract]
Remaining 2020	$ 343
2021	456
2022	371
2023	242
2024	186
Total remaining lease payments	1,598
Less: imputed interest	(267)
Total lease liabilities	$ 1,331
Minimum [Member]
Lessee, Operating Lease, Description [Abstract]
Remaining lease term	1 year
Maximum [Member]
Lessee, Operating Lease, Description [Abstract]
Remaining lease term	5 years
Facility One [Member]
Lessee, Operating Lease, Description [Abstract]
Renewal option term	2 years
Carlsbad Facility [Member]
Lessee, Operating Lease, Description [Abstract]
Renewal option term	5 years

Subsequent Event (Details) - Subsequent Event [Member] - PPP Loans [Member] $ in Thousands	Apr. 22, 2020 USD ($)
PPP Loans [Abstract]
Face amount of debt	$ 2,028
Debt instrument maturity date	May 01, 2022
Interest rate percentage	1.00%